|
1
|
Schmoll HJ and Stein A: Colorectal cancer
in 2013: Towards improved drugs, combinations and patient
selection. Nat Rev Clin Oncol. 11:79–80. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel R, Desantis C and Jemal A:
Colorectal cancer statistics, 2014. CA Cancer J Clin. 64:104–117.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Short KM and Cox TC: Subclassification of
the RBCC/TRIM superfamily reveals a novel motif necessary for
microtubule binding. J Biol Chem. 281:8970–8980. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hatakeyama S: TRIM proteins and cancer.
Nat Rev Cancer. 11:792–804. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ozato K, Shin DM, Chang TH and Morse HC
III: TRIM family proteins and their emerging roles in innate
immunity. Nat Rev Immunol. 8:849–860. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Liu J, Welm B, Boucher KM, Ebbert MT and
Bernard PS: TRIM29 functions as a tumor suppressor in
nontumorigenic breast cells and invasive ER+ breast
cancer. Am J Pathol. 180:839–847. 2012. View Article : Google Scholar
|
|
7
|
Ai L, Kim WJ, Alpay M, Tang M, Pardo CE,
Hatakeyama S, May WS, Kladde MP, Heldermon CD, Siegel EM, et al:
TRIM29 suppresses TWIST1 and invasive breast cancer behavior.
Cancer Res. 74:4875–4887. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fristrup N, Birkenkamp-Demtröder K,
Reinert T, Sanchez-Carbayo M, Segersten U, Malmström PU, Palou J,
Alvarez-Múgica M, Pan CC, Ulhøi BP, et al: Multicenter validation
of cyclin D1, MCM7, TRIM29, and UBE2C as prognostic protein markers
in non-muscle-invasive bladder cancer. Am J Pathol. 182:339–349.
2013. View Article : Google Scholar
|
|
9
|
Kosaka Y, Inoue H, Ohmachi T, Yokoe T,
Matsumoto T, Mimori K, Tanaka F, Watanabe M and Mori M: Tripartite
motif-containing 29 (TRIM29) is a novel marker for lymph node
metastasis in gastric cancer. Ann Surg Oncol. 14:2543–2549. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Qiu F, Xiong JP, Deng J and Xiang XJ:
TRIM29 functions as an oncogene in gastric cancer and is regulated
by miR-185. Int J Clin Exp Pathol. 8:5053–5061. 2015.PubMed/NCBI
|
|
11
|
Tang ZP, Cui QZ, Dong QZ, Xu K and Wang
EH: Ataxia-telangiectasia group D complementing gene (ATDC)
upregulates matrix metalloproteinase 9 (MMP-9) to promote lung
cancer cell invasion by activating ERK and JNK pathways. Tumour
Biol. 34:2835–2842. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tang ZP, Dong QZ, Cui QZ, Papavassiliou P,
Wang ED and Wang EH: Ataxia-telangiectasia group D complementing
gene (ATDC) promotes lung cancer cell proliferation by activating
NF-κB pathway. PLoS One. 8:e636762013. View Article : Google Scholar
|
|
13
|
Jiang T, Tang HM, Lu S, Yan DW, Yang YX
and Peng ZH: Up-regulation of tripartite motif-containing 29
promotes cancer cell proliferation and predicts poor survival in
colorectal cancer. Med Oncol. 30:7152013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sun H, Dai X and Han B: TRIM29 as a novel
biomarker in pancreatic adenocarcinoma. Dis Markers.
2014:3178172014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang L, Heidt DG, Lee CJ, Yang H, Logsdon
CD, Zhang L, Fearon ER, Ljungman M and Simeone DM: Oncogenic
function of ATDC in pancreatic cancer through Wnt pathway
activation and beta-catenin stabilization. Cancer Cell. 15:207–219.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang L, Yang H, Abel EV, Ney GM, Palmbos
PL, Bednar F, Zhang Y, Leflein J, Waghray M, Owens S, et al: ATDC
induces an invasive switch in KRAS-induced pancreatic
tumorigenesis. Genes Dev. 29:171–183. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang L, Yang H, Palmbos PL, Ney G, Detzler
TA, Coleman D, Leflein J, Davis M, Zhang M, Tang W, et al:
ATDC/TRIM29 phosphorylation by ATM/MAPKAP kinase 2 mediates
radio-resistance in pancreatic cancer cells. Cancer Res.
74:1778–1788. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhou ZY, Yang GY, Zhou J and Yu MH:
Significance of TRIM29 and β-catenin expression in non-small-cell
lung cancer. J Chin Med Assoc. 75:269–274. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang Q, Xiao XH, Li M, Li WH, Yu M, Zhang
HB, Ping F, Wang ZX and Zheng J: Chromium-containing traditional
Chinese medicine, Tianmai Xiaoke Tablet improves blood glucose
through activating insulin-signaling pathway and inhibiting PTP1B
and PCK2 in diabetic rats. J Integr Med. 12:162–170. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Subramanian A, Tamayo P, Mootha VK,
Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub
TR, Lander ES, et al: Gene set enrichment analysis: A
knowledge-based approach for interpreting genome-wide expression
profiles. Proc Natl Acad Sci USA. 102:15545–15550. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sho T, Tsukiyama T, Sato T, Kondo T, Cheng
J, Saku T, Asaka M and Hatakeyama S: TRIM29 negatively regulates
p53 via inhibition of Tip60. Biochim Biophys Acta. 1813:1245–1253.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yuan Z, Villagra A, Peng L, Coppola D,
Glozak M, Sotomayor EM, Chen J, Lane WS and Seto E: The ATDC
(TRIM29) protein binds p53 and antagonizes p53-mediated functions.
Mol Cell Biol. 30:3004–3015. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Levine AJ and Oren M: The first 30 years
of p53: Growing ever more complex. Nat Rev Cancer. 9:749–758. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hanahan D and Weinberg RA: The hallmarks
of cancer. Cell. 100:57–70. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Deryugina EI and Quigley JP: Matrix
metalloproteinases and tumor metastasis. Cancer Metastasis Rev.
25:9–34. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yang J and Weinberg RA:
Epithelial-mesenchymal transition: At the crossroads of development
and tumor metastasis. Dev Cell. 14:818–829. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bromberg JF, Wrzeszczynska MH, Devgan G,
Zhao Y, Pestell RG, Albanese C and Darnell JE Jr: Stat3 as an
oncogene. Cell. 98:295–303. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Saxena NK, Sharma D, Ding X, Lin S, Marra
F, Merlin D and Anania FA: Concomitant activation of the JAK/STAT,
PI3K/AKT, and ERK signaling is involved in leptin-mediated
promotion of invasion and migration of hepatocellular carcinoma
cells. Cancer Res. 67:2497–2507. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li L and Shaw PE: Autocrine-mediated
activation of STAT3 correlates with cell proliferation in breast
carcinoma lines. J Biol Chem. 277:17397–17405. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kusaba T, Nakayama T, Yamazumi K, Yakata
Y, Yoshizaki A, Inoue K, Nagayasu T and Sekine I: Activation of
STAT3 is a marker of poor prognosis in human colorectal cancer.
Oncol Rep. 15:1445–1451. 2006.PubMed/NCBI
|
|
31
|
Xiong H, Zhang ZG, Tian XQ, Sun DF, Liang
QC, Zhang YJ, Lu R, Chen YX and Fang JY: Inhibition of JAK1,
2/STAT3 signaling induces apoptosis, cell cycle arrest, and reduces
tumor cell invasion in colorectal cancer cells. Neoplasia.
10:287–297. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Okumura F, Matsunaga Y, Katayama Y,
Nakayama KI and Hatakeyama S: TRIM8 modulates STAT3 activity
through negative regulation of PIAS3. J Cell Sci. 123:2238–2245.
2010. View Article : Google Scholar : PubMed/NCBI
|
